SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,348.93. The last known price of BNB is 702.2705794 USD and is down -0.19 over the last 24 hours. It is currently trading on 3523 active market(s) with $1,103,086,320.06 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Discussion centers on a reported major Binance security breach and withdrawal disruptions, raising concerns about customer fund safety and the exchanges solvency. Traders debate the reported North Korea-linked attribution against speculation about an inside job, while some cite Binances assurances that losses will be covered.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIMs raised full-year outlook, supported by strong freight rates and demand, is fueling discussion about earnings and potential dividends. Traders are also debating the uncertain Hapag-Lloyd takeover and whether a standalone company could return more value to shareholders, with some caution over insider selling and deal risk.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,154,878.82761615 in circulation. The last known price of Hedera is 0.07180731 USD and is down -0.57 over the last 24 hours. It is currently trading on 465 active market(s) with $36,939,739.82 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention amid a prolonged pullback toward the seven-cent area, with traders debating whether continued weakness reflects broader crypto-market pressure and persistent sell supply or presents a buying opportunity. Some holders are accumulating and citing Hederas enterprise and AI use cases, while skeptics point to weak price performance and rallies that have reversed; no single confirmed new catalyst dominates the discussion.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXY is drawing attention around oil-supply headlines, including OPEC+ keeping production targets steady and ongoing concern about Iran-related disruptions to shipping and exports. Traders are watching a potential breakout and call-heavy options activity, while others question how reliably the shares track crude prices.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTYs sharp decline is drawing attention to its exposure to MSTR and Bitcoin, alongside concerns about NAV erosion and shrinking weekly distributions from its option-income strategy. Holders are split between buying the dip for income and betting on a crypto recovery, while critics warn the price and payouts may keep deteriorating and raise the prospect of another reverse split.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiservs earnings miss and reduced 2026 outlook are driving debate, with traders focused on weaker business performance and doubts about managements execution. Some see the sharp selloff as a value opportunity and point to turnaround potential, while speculation about asset sales and a recovery remains unconfirmed.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly beat and raised full-year outlook were overshadowed by softer Q4 organic-growth guidance, which signaled a slowdown and fueled a sharp post-earnings selloff. Traders debate whether the drop reflects justified concern about decelerating growth or an overreaction to otherwise strong results, with some watching for support and a bounce.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,251,444,473.510925 in circulation. The last known price of Stellar is 0.16965209 USD and is down -0.50 over the last 24 hours. It is currently trading on 848 active market(s) with $69,462,156.70 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLMs persistent selloff and failure to hold recent levels dominate the discussion, with many traders blaming heavy token supply or broader crypto weakness; claims of ongoing Stellar Foundation selling are speculation. Bulls are buying dips and pointing to DTCC and other tokenization developments, while skeptics argue those adoption stories have not translated into price strength.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

A sharp selloff in ARM and other semiconductor stocks has traders debating whether the decline is an oversold pullback or a deeper repricing, with some blaming weakness across chipmakers and others pointing to ARMs rich valuation and negative momentum. Dip buyers cite the long-term AI and CPU-demand story, while bears expect more downside.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Attention centers on anticipation for Magnites next earnings report, with traders looking for confirmation that connected-TV advertising can sustain growth. Views are split between dip-buyers expecting strong results and concern over recent weakness, broader ad-tech pressure, and uncertainty around digital advertisings outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

Mustang Bio Ignites Bullish Retail Buzz As FDA Grants Orphan Status To Brain Cancer Drug

Equity

The company is advancing a novel combination of its CAR-T drug MB-101 and oncolytic virus MB-108, with both treatments currently enrolling patients in Phase 1 trials. 

Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

From acquisition news and FDA designations to fresh optimism for struggling stocks, these biotechs piqued Stocktwits users the most on the first trading day of 2025.


Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.

Mustang Bio Inc

Bullish Sentiment

Mustang Bio generated increased retail chatter on Monday after the company said that the FDA had awarded Orphan Drug Designation to its experimental CAR-T drug MB-101 for the treatment of astrocytomas and glioblastoma (GBM), two types of fast-growing brain tumors.The treatment, which targets the IL13Ra2 protein, is currently being studied in a Phase 1 trial.&nbsp;In early results published in Nature Medicine, MB-101 was well-tolerated, with 50% of patients seeing stable disease or better.&nbsp;Among them, two had partial responses, and two others achieved complete responses lasting 7.5 months and more than five and a half years.Mustang is also looking at a combo approach, pairing MB-101 with MB-108, an HSV-1-based oncolytic virus, in a regimen it calls MB-109.&nbsp;Preclinical studies suggest that MB-108 may help modify the tumor microenvironment, essentially turning "cold" tumors into "hot" ones to improve efficiency of MB-101 CAR-T cells.MB-108 already has Orphan Drug status for malignant glioma, and Mustang says the combination could allow MB-101 to move more effectively through the tumor, activate in the right spots, and target cancer cells more precisely.Both MB-101 and MB-108 are still enrolling patients in Phase 1 studies, including one at City of Hope, the other at The University of Alabama at Birmingham.&nbsp;However, moving the MB-109 program forward will depend on whether the company can secure more funding or land a partnership deal.Orphan Drug status gives MB-101 access to several FDA benefits, including seven years of market exclusivity if approved, tax breaks on clinical trial costs, and waived fees, which are all part of a program designed to support treatments for rare conditions affecting fewer than 200,000 people in the U.S.On Stocktwits, retail sentiment for Mustang Bio was ‘extremely bullish’ amid a 105,200% surge in 24-hour message volume.One user on Stocktwits suggested that shares of $MBIO could climb to the $15–$20 range if the company secures a partnership, noting the stock “has life” and is poised to grow, especially for those who bought in below $1.20.<stembedurl>https://stocktwits.com/Invest2live/message/620129007</stembedurl>Another user speculated that a partnership or buyout by a larger pharmaceutical company could be in play, calling the day’s FDA designation “great news” for&nbsp;<a href="https://stocktwits.com/symbol/MBIO">Mustang Bio</a>.<stembedurl>https://stocktwits.com/BostonBigBoyisBack/message/620124257</stembedurl>The stock has declined 68% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.4001
Prev Close	$0.3925
Open	$0.3893
Dividend Yield	0.00%
50-Day Moving Average	$0.4717
Beta	1.09
Avg. Volume	27,716.45
PE Ratio	-0.89

52-Week High	$1.45
52-Week Low	$0.3503
Market Capitalization	$3.03M
EPS (Annual)	-$0.3914
Price to Book	0.40
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

MBIO Fundamentals